This Frost & Sullivan research service titled European Markets for Computer Aided Detection provides an overview of the PCR reagents market for research application, together with its revenues. In addition, it provides a complete analysis of key market drivers, restraints and trends in the market. Finally, it provides strategic solutions to the vendors to gain advantage in this growing market. In this research, Frost & Sullivan's expert analysts thoroughly examine the following markets: mammography CAD, chest CAD and colon CAD.
Expansion of the European CAD Market Dependent on Growth in the Modality Market
Computer Aided Detection (CAD) has significantly expanded its application boundaries. From being a collaborative tool for mammography studies, it has now become established as a comprehensive support tool for cancer diagnosis. In its initial days, CAD was limited to being used with film and digital mammography. However, with advances in technology, CAD is increasingly being used in the detection of lesions for lung/chest applications and with virtual colonoscopy applications.
Success in the concept of computer-aided detection is sometimes, however, overridden by the fact that the industry is hugely dependent on the successes of allied markets to increase the market penetration of CAD. "For instance, the market for colon CAD is dependent on the increasing penetration of virtual colonoscopy and developers of colon CAD are often faced with the challenge of selling the concept of virtual colonoscopy in order to effectively convey the idea of colon CAD," explains the analyst of this research. "Owing to the fact that the industry is relatively nascent and is still in the phase of growth, much remains to be achieved in this market."
CAD Remains Mainstay in Mammo CAD Applications
CAD has maintained its position as a radiologist's third eye since the early 2000s. With increasing awareness of prevention and treatment options available to treat early-stage cancer, screening and detection aids are dominating the 'must have' lists for radiologists. However, the challenge still remains in market expansion and converting the remaining stakeholders of the clinical community to accept CAD as a 'safe bet' in the detection and diagnosis of several types of carcinomas. CAD as a diagnostic tool gained prominence owing to its success in the detection of micro calcifications and masses in mammographic images. "The success story of CAD does not seem limited to the area of breast cancer, as is demonstrated by the significant advances made in the area of development of lung CAD and colon CAD," remarks the analyst. "These solutions are gaining importance among not only radiologists but also practitioners of these clinical specialities."
However, with reimbursement for the procedural uptake of capital-intensive medical imaging modalities such as MRI taking a cut as part of the Deficit Reduction Act of the United States, OEM vendors are in the race to develop and introduce upgraded versions of existing systems that allow building efficiencies into processes. This poses a challenge to market expansion. The most important means to reduce the impact of this act on the industry is to develop solutions that allow for increasing procedural numbers and enhancing efficiencies. In order to fulfil these criteria, CT and MRI machines are being developed with inbuilt capabilities to allow for better diagnostic aid.
(0 items)
